FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 739 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR Mom’s Early-Stage Breast Cancer Discovered When She Undergoes Testing to Donate... August 21, 2019 Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced... October 11, 2024 Study of More than Half a Million Women Links Regular Mammograms... March 10, 2021 Summer Sun Safety Tips September 3, 2020 Load more HOT NEWS No OS Benefit for Active Maintenance Treatment with Olaparib Relative to... Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... Five Questions With…Francisco. Berry Recipes
